3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
352
Neoplasm Metastasis
31
Stomach Neoplasms
30
HER2-positive Breast Cancer
19
Neoplasms
16
Breast Neoplasms, Male
16
Brain Neoplasms
13
Inflammatory Breast Neoplasms
12
Esophageal Neoplasms
10
Colorectal Neoplasms
10
Triple Negative Breast Neoplasms
8
Adenocarcinoma
7
Prostatic Neoplasms
6
Cardiotoxicity
6
Carcinoma, Non-Small-Cell Lung
6
Ovarian Neoplasms
5
Lung Neoplasms
5
Carcinoma, Ductal, Breast
5
Biliary Tract Neoplasms
5
Salivary Gland Neoplasms
4
Pathologic Complete Response
4
Pancreatic Neoplasms
4
Meningeal Neoplasms
4
Colonic Neoplasms
4
Breast Diseases
4
Recurrence
3
Rectal Neoplasms
3
Meningeal Carcinomatosis
3
Gallbladder Neoplasms
3
Carcinoma, Lobular
3
Interventions
Paclitaxel
7
Doxorubicin
5
pembrolizumab
4
pazopanib
4
Gemcitabine
4
Bevacizumab
4
durvalumab
3
Radiotherapy
3
Propranolol
3
Docetaxel
3
regorafenib
2
cemiplimab
2
Surveys and Questionnaires
2
Sunitinib
2
Standard of Care
2
Nivolumab
2
Ifosfamide
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
tremelimumab
1
trebananib
1
trastuzumab duocarmazine
1
talimogene laherparepvec
1
talazoparib
1
spartalizumab
1
sintilimab
1
selinexor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hemangiosarcoma
×
Trastuzumab
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled